Benitec Biopharma, Inc. (BNTC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$12.68+1.93%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BNTC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 154.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 399 industry peers
BNTC — CFO transition
Dated 2026-05-29
Director — Megan Boston: Ms. Boston resigned from the Board but continues as CFO and Secretary.
Why it matters: The earnings report will show Benitec's financial health and plans for the future.
Watch forBenitec announces a date for its next earnings report.
Also watch forNo announcement is made regarding the next earnings report.
Why it matters: Engagement with the FDA is key for moving BB-301 towards approval. This could boost market confidence.
Supportive ifFormal engagement with the FDA occurs mid-year 2026.
Worry ifNo engagement with the FDA is reported by the end of 2026.
Why it matters: Cash management is critical as the company has shown ongoing cash burn. Updates will signal financial health.
Worry ifManagement reports cash burn reduced to below -$3M per quarter.
Less concerning ifCash burn is over -$4.5M each quarter. This shows weak cash management.
Why it matters: Earnings results will show if the company is handling cash well. They will also show if the company is improving its products.
Watch forEarnings report shows a reduction in cash burn, improving from -$4.5M to less than -$3M.
Also watch forEarnings report shows cash burn remains above -$4.5M.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$201 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $552 loss on $10,000 · 5.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,910 loss on $10,000 · 39.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: New results could show the effectiveness of BB-301 and impact its approval chances.
Supportive ifBenitec shares new results from the interim clinical study. This includes Cohort 1 and Cohort 2.
Worry ifNo new interim clinical study results are shared by the end of 2H-2026.
Why it matters: New results will show the effectiveness of BB-301 for treating OPMD. This could impact investor confidence.
Supportive ifNew results for Cohort 1 and Cohort 2 patients will come out in 2H-2026.
Worry ifNo new interim results are provided by the end of 2026.
Why it matters: High cash burn may hurt finances and slow down clinical programs. This is key for stability.
Worry ifQuarterly cash burn remains below $4.5 million.
Less concerning ifQuarterly cash burn exceeds $4.5 million.
Why it matters: If revenue growth speeds up, it may signal a positive shift for Benitec's performance.
Supportive ifHealth Care sector revenue growth is speeding up toward 10% year over year.
Worry ifRevenue growth keeps slowing down below current levels.
Why it matters: Updates on patient enrollment show how the study is going. Good enrollment is key for results.
Supportive ifCohort 2 enrollment meets or exceeds targets. This shows strong interest and safety.
Worry ifEnrollment stops or does not meet targets, raising worries about the study.